Tags: Drug.
Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer. Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius’ development plans.It is a so-called trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.